NCT01127386 - Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions

Cancer Cachexia Syndrome

Interventions

DRUG

Lenalidomide

25mg od, dose reduction according to toxicity

DRUG

Lenalidomide

start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)

OTHER

basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)

twice during study

Trial Locations (1)

Kantonsspital St.Gallen, Sankt Gallen